CytomX Therapeutics, Inc. announced the completion of its public offering of 45,990,567 shares of common stock at an offering price of $5.30 per share, along with pre-funded warrants to purchase 1,179,245 shares of common stock at a price of $5.29999 per warrant. The offering, which closed on March 19, 2026, is expected to generate net proceeds of approximately $234.4 million after deducting underwriting discounts and commissions and estimated offering expenses. The funds raised will be utilized for the continued development of Varseta-M and other pipeline programs, as well as for general corporate purposes and working capital needs. The underwriting agreement includes an option for underwriters to purchase up to 7,075,471 additional shares of common stock at the public offering price within 30 days of the offering's closing date. The offering was made pursuant to a registration statement on Form S-3, which became effective on March 16, 2026. Latham & Watkins LLP provided legal counsel for the offering, ensuring compliance with applicable regulations.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.